{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:25:09Z","timestamp":1781555109358,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40262-018-0725-7","type":"journal-article","created":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T20:23:36Z","timestamp":1544991816000},"page":"659-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-0831","authenticated-orcid":false,"given":"Helena","family":"Edlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ku","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilee A.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Greg","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Aksenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Al-Huniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251\u201362.","journal-title":"Nat Rev Cancer."},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nri953","volume":"2","author":"AL Shaffer","year":"2002","unstructured":"Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920\u201332.","journal-title":"Nat Rev Immunol."},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.12878","volume":"1358","author":"U Gayko","year":"2015","unstructured":"Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, et al. Development of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci. 2015;1358:82\u201394.","journal-title":"Ann N Y Acad Sci."},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332 (Nature Publishing Group).","journal-title":"Nat Rev Cancer."},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240\u201352.","journal-title":"J Pharmacol Exp Ther."},{"key":"725_CR6","first-page":"1","volume":"6736","author":"M Wang","year":"2017","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017;6736:1\u20139.","journal-title":"Lancet."},{"key":"725_CR7","unstructured":"US FDA. Calquence (acalabrutinib) Label. 2017. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf\n                    \n                  . Accessed 18 Sept 2018."},{"key":"725_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323\u201332.","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"725_CR9","first-page":"4997","volume":"130","author":"H Edlund","year":"2017","unstructured":"Edlund H, Andrew M, Jin F, Patel P, Masson E, Slatter JG, et al. Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies. Blood. 2017;130(Suppl 1):4997.","journal-title":"Blood."},{"key":"725_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401\u201321.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"725_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development\u2014Part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2:e38.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bcp.12756","volume":"81","author":"N Al-Huniti","year":"2016","unstructured":"Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol. 2016;81:89\u2013100.","journal-title":"Br J Clin Pharmacol."},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2125.2009.03520.x","volume":"68","author":"P Ravva","year":"2009","unstructured":"Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol. 2009;68:669\u201381.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 1","key":"725_CR15","first-page":"1268","volume":"130","author":"F Jin","year":"2017","unstructured":"Jin F, Yin M, Mandava V, Edlund H, Andrew M, Patel P, et al. Exposure-response of the Bruton\u2019s tyrosine kinase inhibitor, acalabrutinib in the treatment of hematologic malignancies. Blood. 2017;130(Suppl 1):1268.","journal-title":"Blood."},{"key":"725_CR16","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna; 2015. \n                    http:\/\/www.r-project.org\/\n                    \n                  ."},{"key":"725_CR17","volume-title":"NONMEM user\u2019s guides (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guides (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"key":"725_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Programs Biomed."},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1517\/17425250902773426","volume":"5","author":"JW Yates","year":"2009","unstructured":"Yates JW, Jones RO, Walker M, Cheung SA. Structural identifiability and indistinguishability of compartmental models. Expert Opin Drug Metab Toxicol. 2009;5:295\u2013302.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"725_CR21","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2011.","edition":"4"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0725-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T19:24:39Z","timestamp":1576524279000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0725-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0725-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"17 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The underlying clinical studies were sponsored by Acerta Pharma (a member of the AstraZeneca group).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Helena Edlund, Sun Ku Lee, Marilee A. Andrew, J. Greg Slatter, Sergey\u00a0Aksenov and Nidal Al-Huniti were all employed by Acerta Pharma or AstraZeneca at the time this work was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}